Publication
Phase I Study of Apitolisib (GDC-0980), Dual Phosphatidylinositol-3-Kinase and Mammalian Target of Rapamycin Kinase Inhibitor, in Patients with Advanced Solid Tumors.
Authors not recorded
- Source
- PubMed
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CIVIC-20260908-000001
Abstract
Abstract (excerpt)
Only the opening of the abstract is shown; abstract text may carry publisher copyright.
Data not yet available
Linked entities
Linked entities (6)
How each link was made (MeSH, dictionary, registry reference, curation…) and whether it has been validated. Candidate links are not counted in entity statistics.
Validated 6
- cancerHead and Neck Squamous Cell Carcinomacivic_curation1.00
- cancerMalignant Neoplasmcivic_curation1.00
- drugApitolisibcivic_curation1.00
- genePIK3CAcivic_curation1.00
- variantPIK3CA E542Kcivic_curation1.00
- variantPIK3CA E545Kcivic_curation1.00
Curated evidence
Evidence citing this paper (2)
- Source
- CIViC — Clinical Interpretation of Variants in Cancer
- Dataset
- CIViC evidence items
- Version
- civic-2026-09-08
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Evidence
- expert curation
- License
- CC0 1.0
- PMID
- 26787751
- Run
- ING-CIVIC-20260908-000001
| Therapy | Cancer | Type | Level | Direction · significance | Rating (1–5) | Status | Evidence | Source |
|---|---|---|---|---|---|---|---|---|
| PIK3CA E542K1 | ||||||||
| Apitolisib | Head and Neck Squamous Cell Carcinoma | Predictive | C | Supports Sensitivity Response | 2 | accepted | EID1549Phase 1 study with the dual PI3K/mTOR inhibitor apitolisib. 120 patients were treated at doses between 2 and 70mg. Of the 14 evaluable patients with PIK3CA mutations total, there were 3 PRs (1 confirm… (full text at CIViC) PMID 26787751 · Dolly et al., 2016 · Open in CIViC | civic |
| PIK3CA E545K1 | ||||||||
| Apitolisib | Malignant NeoplasmALIAS | Predictive | C | Supports Sensitivity Response | 1 | accepted | EID1550Phase 1 study with the dual PI3K/mTOR inhibitor apitolisib. 120 patients were treated at doses between 2 and 70mg. Of 45 evaluable patients receiving 40mg, two patients with E545K PIK3CA mutation (one… (full text at CIViC) PMID 26787751 · Dolly et al., 2016 · Open in CIViC | civic |